189
Participants
Start Date
December 31, 2009
Primary Completion Date
April 30, 2012
Study Completion Date
April 30, 2012
HPN-100
Part B: 6 mL BID for 16 weeks.
Placebo
Part B: same as experimental arm
Concorde Medical Group PLLC, New York
NYU Medical Center, New York
Mount Sinai Medical Center, New York
Columbia University Medical Center / Center for Liver Disease and Transplantation, New York
New York Medical College / Westchester Medical Center, Valhalla
University of Rochester Medical Center, Rochester
University of Pennsylvania, Philadelphia
Georgetown University Hospital, Washington D.C.
University of Maryland, Baltimore
University of Virginia Health System, Charlottesville
University of Miami / Center for Liver Diseases, Miami
Tampa General Hospital, Tampa
The Digestive Disease Center at Vanderbilt, Nashville
Cleveland Clinic, Cleveland
University of Cincinnati / Division of Digestive Diseases, Cincinnati
Indiana University, Indianapolis
Henry Ford Hospital / Department of Gastroenterology, Detroit
University of Iowa Hospitals and Clinics, Iowa City
University of Wisconsin Hospital & Clinics, Madison
The University of Chicago Medical Center, Chicago
University of Kansas Medical Center, Kansas City
University of Nebraska Medical Center, Omaha
Tulane University Health Science Center, New Orleans
Methodist Dallas Medical Center, Dallas
UT Southwestern Medical Center, Dallas
Baylor College of Medicine-St. Luke's Episcopal Hospital, Houston
Stanford University Medical Center, Division of Gastroenterology and Hepatology, Palo Alto
Dartmouth Hitchcock Medical Center, Lebanon
Lead Sponsor
Amgen
INDUSTRY